First Tracks climbs on ‘impressive’ celiac study data

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 12 Oct, 21:26 UTC

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.

science

Sources

• T2First Tracks climbs on ‘impressive’ celiac study dataBioPharma Dive / Healthcare Dive / MedTech Dive12 Oct, 21:26